64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
JAMA neurology
·
2014-04-01
Identifying a clinical distinction between the invariably lethal prion disease Creutzfeldt-Jakob disease (CJD) and nonprion rapidly progressive dementias is important and sometimes difficult; thus, reliable tools for diagnosis are in great demand. 4 key findings →
Design: cohort study
Participants: 30
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
64/100
✓ Peer-reviewed
alzhub usefulness score 64 out of 100.
·
JAMA neurology
·
2015-10-01
Among the 128 study participants, the 104 patients with early PD had a different CSF pattern compared with the 13 patients with progressive supranuclear palsy (baseline area under the receiver operating characteristic curve, 0.87; P < .0001) and the 30 control participants (baseline area under the receiver operating characteristic curve, 0.69; P = .0021). 2 key findings →
Design: cohort study
Participants: 104
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Perioperative changes in plasma amyloid do not appear to be associated with postoperative delirium. 5 key findings →
Design: cohort study
Participants: 100
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
63/100
✓ Peer-reviewed
alzhub usefulness score 63 out of 100.
·
PharmacoEconomics
·
2024-11-01
Mean annual costs for individuals with clinically diagnosed AD were SEK 99,906, SEK 290,972, SEK 479,524, and SEK 795,617 in mild cognitive impairment (MCI), mild, moderate, and severe AD. 1 key finding →
Design: cohort
Participants: 95,853
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
We enrolled a cohort of 1070 PSEN1 E280A mutation carriers and 1074 non-carriers with baseline assessments; of these participants, longitudinal measures (with a mean follow-up of 6 years) were available for 242 mutation carriers and 262 non-carriers. 1 key finding →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
62/100
✓ Peer-reviewed
alzhub usefulness score 62 out of 100.
·
JAMA network open
·
2025-05-01
Lobar CMB counts and the presence of CAA were associated with downstream AD plasma biomarkers, including p-tau217 (β = 0.12 [95% CI, 0.05-0.18] and 0.29 [95% CI, 0.12-0.47], respectively), GFAP (β = 0.07 [95% CI, 0.03-0.12] and 0.20 [95% CI, 0.09-0.31], respectively), and NfL (β = 0.07 [95% CI, 0.03-0.11] and 0.16 [95% CI, 0.06-0.25], respectively) with and without the mediation of Aβ uptake on PET (indirect effect: lobar CMBs-p-tau217, 59.8% [β = 0.07 (95% CI, 0.03-0.11)]; lobar CMBs-GFAP, 49.3% [β = 0.04 (95% CI, 0.01-0.06)]; lobar CMBs-NfL, 20.9% [β = 0.01 (95% CI, 0.01-0.03)]; CAA-p-tau217, 50.9% [β = 0.15 (95% CI, 0.06-0.24)]; CAA-GFAP, 39.2% [β = 0.08 (95% CI, 0.03-0.13)]; CAA-NfL, 19.2% [β = 0.03 (95% CI, 0.01-0.05)]). 4 key findings →
Design: cohort study
Participants: 1,708
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cerebrospinal fluid neurogranin was increased in patients with Alzheimer's disease dementia (P < 0.001), progressive mild cognitive impairment (P < 0.001) and stable mild cognitive impairment (P < 0.05) compared with controls, and in Alzheimer's disease dementia (P < 0.01) and progressive mild cognitive impairment (P < 0.05) compared with stable mild cognitive impairment. 2 key findings →
Design: longitudinal study
Participants: 95
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
CSF Aβ levels are altered in a subset of patients with early PD and relate to memory impairment. 4 key findings →
Design: longitudinal study
Participants: 20
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Cerebrospinal fluid (CSF) neurofilament light (NFL) is a marker of axonal degeneration. 2 key findings →
Design: longitudinal study
Participants: 144
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
CSF apoB markedly associates with early tau dysregulation in asymptomatic subjects and identifies at-risk individuals predisposed to develop visuospatial cognitive decline over time. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
A simple blood test for GFAP, a protein released by activated star-shaped brain support cells called astrocytes, could identify which patients with mild memory problems had underlying Alzheimer's pathology and predict, years in advance, who would go on to develop Alzheimer's dementia. 4 key findings →
Design: cohort
Participants: 160
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
61/100
✓ Peer-reviewed
alzhub usefulness score 61 out of 100.
·
JAMA neurology
·
2017-01-01
These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
JAMA network open
·
2023-11-01
These findings suggest that increases in certain plasma AD biomarkers are associated with NP in WLWH and WLWOH and may be associated with later onset of AD, and measuring these biomarkers could be a pivotal advancement in monitoring aging brain health and development of AD among women with and without HIV. 5 key findings →
Design: cohort study
Participants: 307
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
60/100
✓ Peer-reviewed
alzhub usefulness score 60 out of 100.
·
Nature aging
·
2022-11-28
The role of microglia in tau accumulation is currently unclear but could provide an important insight into the mechanisms underlying Alzheimer's disease (AD) 1 . 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
We investigated the effects of matrix type and reagent batch changes on diagnostic performances and longitudinal trajectories of brain-derived tau (BD-tau). 4 key findings →
Design: longitudinal study
Participants: 26
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
PD patients who develop poor outcomes show lower DTI-ALPS, potentially reflecting impaired glymphatic clearance. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Progressive cerebral volume loss on MRI is a hallmark of Alzheimer's disease and has been widely used as an outcome measure in clinical trials, with the prediction that disease-modifying treatments would slow loss. 1 key finding →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Our findings support an association of APOE ɛ4 and p-tau181 with preclinical AD and hippocampus functioning. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
We identified a series of transmembrane proteins, proteins associated with or anchored to the plasma membrane, and proteins involved in or connected to synaptic vesicle transport to be associated with CSF biomarkers of amyloid and tau pathology in AD. 4 key findings →
Design: cohort study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Insulin, insulin-like growth factors (IGF) and their receptors are highly expressed in the adult hippocampus. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
56/100
✓ Peer-reviewed
alzhub usefulness score 56 out of 100.
·
PharmacoEconomics
·
2026-04-01
This study estimated the utilization and lifetime costs of formal care for AD dementia using longitudinal register data. 4 key findings →
Design: cohort
Participants: 20,366
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Changes in CSF biomarker levels may identify early neurodegenerative processes of Alzheimer disease. 2 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
53/100
✓ Peer-reviewed
alzhub usefulness score 53 out of 100.
·
Resuscitation
·
2024-12-03
We studied the promising Alzheimer biomarker plasma tau phosphorylated at threonine 231 (p-tau231) in a cohort of cardiac arrest patients who survived to intensive care to predict long-term neurological outcomes. 4 key findings →
Design: cohort study
Participants: 425
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Low levels of cerebrospinal fluid (CSF) beta-amyloid 1-42 (Abeta42) and high total tau (T-tau) are diagnostic for manifest Alzheimer's disease. 4 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Biomarkers in Alzheimer's disease (AD) have the potential to allow early and more accurate diagnosis, predict disease progression, stratify individuals and track response to candidate therapies in drug trials. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 32,180 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.